GAIN THERAPEUTICS, INC Revenue from Contract with Customer, Excluding Assessed Tax
GAIN THERAPEUTICS, INC (GANX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $55.18 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-03-27
- GAIN THERAPEUTICS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2023-12-31 was $0.00.
- GAIN THERAPEUTICS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2023-09-30 was $0.00.
- GAIN THERAPEUTICS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- GAIN THERAPEUTICS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2023-03-31 was $55.18K, a 47.00% increase year-over-year.
- GAIN THERAPEUTICS, INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $55.18K, a 58.40% decline from fiscal 2022.
- GAIN THERAPEUTICS, INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $132.64K, a 0.96% decline from fiscal 2021.
- GAIN THERAPEUTICS, INC revenue from contract with customer, excluding assessed tax for fiscal 2021 was $133.93K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $55.18K 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $55.18K 10-Q · filed 2024-11-14 | $55.18K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $55.18K 10-Q · filed 2024-08-08 | $55.18K derived: sum of 3 quarters · filed 2024-08-08 | $55.18K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $55.18K 10-Q · filed 2024-05-14 | $55.18K derived: sum of 2 quarters · filed 2024-05-14 | $55.18K derived: sum of 3 quarters · filed 2024-05-14 | $150.28K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $0.00 derived: sum of 2 quarters · filed 2024-03-26 | $95.10K derived: sum of 3 quarters · filed 2024-03-26 | $132.64K 10-K · filed 2024-03-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $95.10K derived: sum of 2 quarters · filed 2023-11-14 | $132.64K 10-Q · filed 2023-11-14 | $168.98K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $95.10K 10-Q · filed 2023-08-10 | $132.64K 10-Q · filed 2023-08-10 | $168.98K derived: sum of 3 quarters · filed 2023-08-10 | $184.95K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $37.54K 10-Q · filed 2023-05-12 | $73.88K derived: sum of 2 quarters · filed 2023-05-12 | $89.85K derived: sum of 3 quarters · filed 2023-05-12 | $171.47K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $36.34K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $52.31K derived: sum of 2 quarters · filed 2023-03-23 | $133.93K derived: sum of 3 quarters · filed 2023-03-23 | $133.93K 10-K · filed 2023-03-23 |
| 2021-09-30 | $15.97K 10-Q · filed 2022-11-10 | $97.59K derived: sum of 2 quarters · filed 2022-11-10 | $97.59K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $81.62K 10-Q · filed 2022-08-08 | $81.62K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |